545 related articles for article (PubMed ID: 26549336)
1. Rush immunotherapy for wasp venom allergy seems safe and effective in patients with mastocytosis.
Verburg M; Oldhoff JM; Klemans RJ; Lahey-de Boer A; de Bruin-Weller MS; Röckmann H; Sanders C; Bruijnzeel-Koomen CA; Pasmans SG; Knulst AC
Eur Ann Allergy Clin Immunol; 2015 Nov; 47(6):192-6. PubMed ID: 26549336
[TBL] [Abstract][Full Text] [Related]
2. Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective.
Goldberg A; Yogev A; Confino-Cohen R
Int Arch Allergy Immunol; 2011; 156(1):90-8. PubMed ID: 21447964
[TBL] [Abstract][Full Text] [Related]
3. Safety of Ultrarush Venom Immunotherapy: Comparison Between Children and Adults.
Nittner-Marszalska M; Cichocka-Jarosz E; Małaczyńska T; Kraluk B; Rosiek-Biegus M; Kosinska M; Pawłowicz R; Lis G
J Investig Allergol Clin Immunol; 2016; 26(1):40-7. PubMed ID: 27012015
[TBL] [Abstract][Full Text] [Related]
4. Anaphylaxis after hymenoptera sting: is it venom allergy, a clonal disorder, or both?
Castells MC; Hornick JL; Akin C
J Allergy Clin Immunol Pract; 2015; 3(3):350-5. PubMed ID: 25858055
[TBL] [Abstract][Full Text] [Related]
5. Fatal anaphylactic sting reaction in a patient with mastocytosis.
Wagner N; Fritze D; Przybilla B; Hagedorn M; Ruëff F
Int Arch Allergy Immunol; 2008; 146(2):162-3. PubMed ID: 18204283
[TBL] [Abstract][Full Text] [Related]
6. Rush hymenoptera venom immunotherapy is efficacious and safe.
Pasaoglu G; Sin BA; Misirligil Z
J Investig Allergol Clin Immunol; 2006; 16(4):232-8. PubMed ID: 16889280
[TBL] [Abstract][Full Text] [Related]
7. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses.
Ruëff F; Wenderoth A; Przybilla B
J Allergy Clin Immunol; 2001 Dec; 108(6):1027-32. PubMed ID: 11742283
[TBL] [Abstract][Full Text] [Related]
8. Venom immunotherapy for preventing allergic reactions to insect stings.
Boyle RJ; Elremeli M; Hockenhull J; Cherry MG; Bulsara MK; Daniels M; Oude Elberink JN
Cochrane Database Syst Rev; 2012 Oct; 10(10):CD008838. PubMed ID: 23076950
[TBL] [Abstract][Full Text] [Related]
9. The VISYT trial: Venom Immunotherapy Safety and Tolerability with purified vs nonpurified extracts.
Bilò MB; Severino M; Cilia M; Pio A; Casino G; Ferrarini E; Campodonico P; Milani M
Ann Allergy Asthma Immunol; 2009 Jul; 103(1):57-61. PubMed ID: 19663128
[TBL] [Abstract][Full Text] [Related]
10. Fatal Anaphylaxis to Yellow Jacket Stings in Mastocytosis: Options for Identification and Treatment of At-Risk Patients.
Vos BJPR; van Anrooij B; van Doormaal JJ; Dubois AEJ; Oude Elberink JNG
J Allergy Clin Immunol Pract; 2017; 5(5):1264-1271. PubMed ID: 28499778
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the Safety Profiles of 3 Different Hymenoptera Venom Immunotherapy Protocols: A Retrospective 2-Center Study of 143 Patients.
Pospischil IM; Kagerer M; Cozzio A; Angelova-Fischer I; Guenova E; Ballmer-Weber B; Hoetzenecker W
Int Arch Allergy Immunol; 2020; 181(10):783-789. PubMed ID: 32781451
[TBL] [Abstract][Full Text] [Related]
12. Pre-emptive Evaluation of Venom Allergy in a Patient with Systemic Mastocytosis.
Gülen T; Akin C
Acta Derm Venereol; 2018 Jan; 98(1):149-150. PubMed ID: 28902950
[No Abstract] [Full Text] [Related]
13. Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy.
Roll A; Hofbauer G; Ballmer-Weber BK; Schmid-Grendelmeier P
J Investig Allergol Clin Immunol; 2006; 16(2):79-85. PubMed ID: 16689180
[TBL] [Abstract][Full Text] [Related]
14. Anaphylactic Reactions After Discontinuation of Hymenoptera Venom Immunotherapy: A Clonal Mast Cell Disorder Should Be Suspected.
Bonadonna P; Zanotti R; Pagani M; Bonifacio M; Scaffidi L; Olivieri E; Franchini M; Reccardini F; Costantino MT; Roncallo C; Mauro M; Boni E; Rizzini FL; Bilò MB; Marcarelli AR; Passalacqua G
J Allergy Clin Immunol Pract; 2018; 6(4):1368-1372. PubMed ID: 29258788
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of a Progressively Prolonged Maintenance Interval of Venom Immunotherapy.
Kontou-Fili K; Pitsios C; Kompoti E; Giannakopoulos D; Kouridakis S
Int Arch Allergy Immunol; 2018; 176(1):39-43. PubMed ID: 29649812
[TBL] [Abstract][Full Text] [Related]
16. Adverse reactions in venom immunotherapy protocols: conventional versus ultra-rush.
Selcuk A; Baysan A; Yesillik S; Demirel F; Kartal O; Gulec M; Musabak U; Sener O
Ann Med; 2022 Dec; 54(1):2321-2325. PubMed ID: 36111408
[TBL] [Abstract][Full Text] [Related]
17. A simple 3-day "rush" venom immunotherapy protocol: documentation of safety.
Kalogeromitros D; Makris M; Koti I; Chliva C; Mellios A; Avgerinou G; Theoharides TC
Allergol Immunopathol (Madr); 2010; 38(2):69-73. PubMed ID: 19853357
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy of venom immunotherapy.
Hafner T; DuBuske L; Kosnik M
Ann Allergy Asthma Immunol; 2008 Feb; 100(2):162-5. PubMed ID: 18320918
[TBL] [Abstract][Full Text] [Related]
19. Rush venom immunotherapy in patients experiencing recurrent systemic reactions to conventional venom immunotherapy.
Goldberg A; Confino-Cohen R
Ann Allergy Asthma Immunol; 2003 Oct; 91(4):405-10. PubMed ID: 14582821
[TBL] [Abstract][Full Text] [Related]
20. Venom immunotherapy in patients with clonal mast cell disorders: IgG4 correlates with protection.
Jarkvist J; Salehi C; Akin C; Gülen T
Allergy; 2020 Jan; 75(1):169-177. PubMed ID: 31306487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
